Shamburg News · 8-K filed Nov 10, 2026, 5:30 PM EST
Spero Therapeutics Director Patrick Vink Resigns; William Ho Appointed Class II Director
SPRO · Spero Therapeutics, Inc.
- Leadership change
- Materiality: medium
On November 9, 2026, Patrick Vink, M.D. notified the Board of Spero Therapeutics, Inc. of his resignation as a Class II director, including as Chair of the Nominating and Corporate Governance Committee and from the Compensation Committee, effective November 10, 2026. The Company stated the resignation was not the result of any disagreement. The Board appointed William Ho, M.D., Ph.D. as a Class II director effective November 10, 2026, to fill the vacancy, with an annual cash retainer of $40,000 and an option to purchase 100,000 shares of common stock.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001193125-26-455789.
Written from the filing by Shamburg Markets. Figures are as reported by the company.